venetoclax

Overview

Selective small-molecule BCL2 inhibitor.

Evidence in the corpus

• In the 1,148-patient CLL map, TP53 mutation in the absence of 17p deletion was not associated with adverse outcomes in U-CLL, consistent with the contemporary ibrutinib/venetoclax treatment era reducing the isolated TP53-mutation prognostic impact PMID:35927489.
• BCL2 — the venetoclax target — is recurrently involved through Ig-locus translocations predominantly in M-CLL (5/88 WGS cases, 5.7%) via aberrant V(D)J recombination PMID:35927489.

Resistance mechanisms

• Not directly characterized in this corpus.

Cancer types (linked)

• CLLSLL

Sources

• PMID:35927489

This page was processed by crosslinker on 2026-04-08.